AST 005

Drug Profile

AST 005

Alternative Names: AST-005

Latest Information Update: 21 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Exicure
  • Class Anti-inflammatories; Antipsoriatics; Immunotherapies; Nucleic acids; Skin disorder therapies; Small molecules
  • Mechanism of Action Tumour necrosis factor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Psoriasis

Highest Development Phases

  • Phase I Psoriasis

Most Recent Events

  • 31 Oct 2017 Exicure completes a phase Ib trial in Psoriasis in Germany in the third quarter of 2017
  • 12 Dec 2016 Exicure and Purdue Pharma agree to co-develop AST 005 for Plaque psoriasis
  • 12 Dec 2016 Exicure has patents pending for AST 005
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top